Cidara Therapeutics, Inc. (CDTX)
After hours:
| Previous Close | 0.7222 |
| Open | 0.7200 |
| Bid | 0.6959 x 600 |
| Ask | 0.7643 x 1000 |
| Day's Range | 0.7151 - 0.7499 |
| 52 Week Range | 0.5930 - 1.4800 |
| Volume | |
| Avg. Volume | 701,964 |
| Market Cap | 65.427M |
| Beta (5Y Monthly) | 1.01 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.3900 |
| Earnings Date | Apr 19, 2024 - Apr 20, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 5.60 |
GlobeNewswireCidara Therapeutics Presents Promising New Data on Novel Drug-Fc Conjugate Candidates at the American Association for Cancer Research (AACR) Annual Meeting 2024
- Multispecific CD73/PD-1 DFC demonstrates improved tumor reduction compared to PD-1 monotherapy in nonclinical study - CCR5-targeting DFC demonstrates potent efficacy in colorectal cancer mouse model - Late-breaking CBO421 data demonstrates improved efficacy compared to oleclumab in human triple-negative breast cancer cell lines SAN DIEGO, April 05, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop dr
- GlobeNewswire
Cidara Therapeutics to Present Preclincal Data on Multiple Novel Drug-Fc Conjugate Candidates at American Association for Cancer Research (AACR) Annual Meeting 2024
Abstracts to include preclinical data on several drug-Fc conjugate (DFC) candidates including multispecific CD73/PD-1 DFC, CCR5 targeting DFC and CBO421 (CD73 targeting DFC)SAN DIEGO, March 06, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced the company
GuruFocus.comSteven Cohen's Point72 Adds Cidara Therapeutics to Its Portfolio
Steven Cohen (Trades, Portfolio)'s investment firm, Point72, has recently expanded its portfolio with the addition of Cidara Therapeutics Inc (NASDAQ:CDTX). On December 31, 2023, Point72 acquired 1,250,228 shares of the biotechnology company, reflecting a new position in the firm's diverse investment landscape. The transaction was executed at a trade price of $0.794 per share, marking a strategic move by one of the industry's leading investment entities.
